<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002157</url>
  </required_header>
  <id_info>
    <org_study_id>MEC09-2-075</org_study_id>
    <secondary_id>NL27372.068.09</secondary_id>
    <nct_id>NCT01002157</nct_id>
  </id_info>
  <brief_title>The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification</brief_title>
  <acronym>VitaK-CAC</acronym>
  <official_title>The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VitaK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both Coronary Artery Calcification (CAC)and its annual progression are a strong predictors of
      cardiovascular events. The development of arterial calcification results from imbalance
      between calcification promoting and inhibiting factors. An important inhibitor of
      calcification is Matrix Gla Protein (MGP): a protein present in the vascular wall where it is
      synthesized by Vascular Smooth Muscle Cells (VSMC). MGP requires Vitamin K-mediated
      carboxylation to function properly. Deficiency of Vitamin K has been demonstrated to cause
      arterial calcification and a diet containing large amounts of Vitamin K2 was associated with
      lower CAC and cardiovascular risk. In animal studies, active supplementation of Vitamin K2
      caused regression of existing arterial calcification. Therefore, the aim of this randomized,
      double-blind, placebo-controlled clinical trial is to investigate whether daily
      supplementation of Vitamin K2 (Menaquinone-7) to patients with established CAC will lead to a
      decreased progression-rate of CAC after 24 months of follow-up in comparison to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Artery Calcification-score progression</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial Stiffness measured by Carotid-Femoral Pulse-Wave Velocity</measure>
    <time_frame>0, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid Intima Media Thickness</measure>
    <time_frame>0, 12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin K2 supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Menaquinone-7 (Vitamin K2)</intervention_name>
    <description>Menaquinone-7 (Vitamin K2)</description>
    <arm_group_label>Vitamin K2 supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>Capsules containing no Menaquinone-7</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Baseline Coronary Computed Tomographic Angiography (CCTA) of sufficient quality

          -  Baseline Agatston calciumscore 100 - 400

        Exclusion Criteria:

          -  Baseline-scan of insufficient quality

          -  Heart rate greater than 70 beats per minute during first scan.(despite adequate
             treatment with metoprolol)

          -  Chronic or paroxysmal Atrial Fibrillation

          -  Presence or scheduled coronary revascularization procedure

          -  History of myocardial infarction or stroke.

          -  Presence of Diabetes Mellitus.

          -  Known kidney disease or a Glomerular Filtration Rate (GFR)MDRD &lt; 60 ml/min/1.73m2

          -  Malignant disease (exception: treated basal-cell or squamous cell carcinoma).

          -  Use of Vitamin K antagonists.

          -  A life-expectancy &lt; 2 years

          -  Pregnancy or wish to become pregnant in the near future.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abraham Kroon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter de Leeuw, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abraham Kroon, MD, PhD</last_name>
    <phone>+31433877005</phone>
    <email>aa.kroon@MUMC.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Abraham Kroon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barry van Varik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Calcification</keyword>
  <keyword>Vitamin K</keyword>
  <keyword>Trial</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

